Guidance for
testing utilization

Expert interpretation of chromosome abnormalities

Lymphomas are among the most complex diseases to recognize and diagnose because they are pathologically complex, with features that overlap with reactive/inflammatory conditions and other nonhematologic malignancies.

By the numbers


There are currently over 30 identified subtypes of T-cell neoplasms, which can make diagnosis difficult.


T-cell malignancies account for approximately 12% of all non-Hodgkin's lymphomas.


Non-Hodgkin's lymphoma is the seventh most common type of cancer in the U.S.

Clinical expertise in lymphomas

To assist clinicians with lymphoma diagnosis, Mayo Clinic has a highly experienced, nine-member hematopathology section focusing on lymphoma diagnosis, which diagnoses more than 3,000 lymphoma cases per year.

Paul Kurtin, M.D., consultant in Hematopathology, provides an overview of the lymphoma consultation services available through Mayo Clinic Laboratories.

IGHV and TP53 
sequencing: Clinical utility in chronic lymphocytic leukemia (CLL)

Our goals today are, first of all, to understand the use of prognostic markers in CLL patients; second, to highlight the importance of molecular analyses for IGHV and TP53 sequencing in CLL patients; third, to understand how IGHV mutation analysis provides prognostic information in CLL and can help inform clinicians about possible treatment decisions; and, finally, recognizing that TP53 mutations identified by sequencing studies are associated with poor outcomes, since those patients are more likely to be resistant to standard therapeutic regimens.

Additional resources